ADHD Medication Types: Stimulants vs. Non-Stimulants
If you or someone you care about has been diagnosed with ADHD, one of the first questions that comes up is what medication options actually exist. The answer is not as simple as a single prescription. There are two broad categories of ADHD medication, and the difference between them matters both clinically and practically. This page explains how stimulants and non-stimulants work, who each type is typically prescribed for, and what the decision-making process looks like with a psychiatrist.
Why Medication Type Matters in ADHD Treatment
ADHD medication is not one-size-fits-all. Stimulant medications are the most studied and most commonly prescribed class, but non-stimulant options exist and are clinically appropriate for a significant portion of patients. According to the National Institute of Mental Health, ADHD affects approximately 4.4 percent of adults in the United States, and medication is a central component of treatment for many of them. Choosing between stimulant and non-stimulant options depends on a patient’s symptom profile, medical history, substance use history, co-occurring conditions, and personal preferences. A psychiatrist evaluates all of these factors before recommending a starting point.
Stimulant Medications: How They Work and What to Expect
Stimulant medications work by increasing the availability of dopamine and norepinephrine in the brain. These neurotransmitters are central to attention regulation, impulse control, and executive function. When they are not available in sufficient amounts or are not being used efficiently, the symptoms of ADHD become pronounced. Stimulants address this at the neurochemical level, which is why they produce noticeable effects relatively quickly compared to most psychiatric medications.
There are two main classes of stimulants used in ADHD treatment.
Amphetamine-Based Stimulants
Amphetamine compounds include mixed amphetamine salts and lisdexamfetamine. Brand names in this class include Adderall, Adderall XR, and Vyvanse. These medications are available in immediate-release and extended-release formulations. Immediate-release versions typically last four to six hours. Extended-release formulations are designed to cover the full workday and often last ten to fourteen hours, depending on the specific medication and the individual’s metabolism.
Vyvanse (lisdexamfetamine) is a prodrug, meaning it is inactive until metabolized by the body. This design tends to produce a smoother onset and a lower abuse potential compared to immediate-release amphetamines, which is one reason it is frequently prescribed for adults.
Methylphenidate-Based Stimulants
Methylphenidate works through a similar mechanism but is structurally distinct from amphetamines. Brand names include Ritalin, Concerta, Metadate, and Focalin. Like amphetamines, methylphenidate is available in short-acting and long-acting formulations. Concerta is an extended-release form designed to last up to twelve hours. Focalin is a refined version of methylphenidate that some patients tolerate more comfortably than standard formulations.
Some patients respond better to methylphenidate than to amphetamines, and vice versa. There is no reliable way to predict this in advance, which is why initial medication selection involves monitoring response and adjusting accordingly. This is a normal part of ADHD treatment, not a sign that treatment is failing.
Common Side Effects of Stimulants
Stimulants are generally well tolerated, but side effects occur and are worth understanding before starting treatment. The most frequently reported include reduced appetite, difficulty falling asleep if taken too late in the day, mild increases in heart rate and blood pressure, dry mouth, and irritability as the medication wears off. Most side effects are manageable through dose adjustment, timing changes, or switching formulations. A psychiatrist monitors these variables during follow-up appointments and makes adjustments based on reported experience.
Stimulants are classified as Schedule II controlled substances under federal law. This means they require a specific type of prescription and cannot be called in by phone to a pharmacy. They also carry a risk of misuse and dependence, which is one factor a prescribing psychiatrist considers in the evaluation process. For patients with a personal or family history of substance use disorders, this discussion is an important part of the medication conversation rather than a barrier to treatment. Many patients in recovery are successfully and safely treated with stimulants under appropriate psychiatric supervision.
For a detailed overview of ADHD as a condition, including diagnostic criteria and treatment options beyond medication, the ADHD covers the full picture.
Non-Stimulant Medications: An Alternative That Works
Non-stimulant ADHD medications do not carry the same controlled substance classification as stimulants. They work through different mechanisms, have different onset timelines, and are appropriate for a different patient profile. They are not a second-best option. For some patients, they are the right first choice.
Atomoxetine (Strattera)
Atomoxetine is a selective norepinephrine reuptake inhibitor, meaning it increases norepinephrine availability in the brain without affecting dopamine in the same way stimulants do. It is the only non-stimulant medication FDA-approved specifically for ADHD in both children and adults. Unlike stimulants, which produce effects within hours of the first dose, atomoxetine requires consistent daily use over four to eight weeks before the full benefit becomes apparent. This is similar to the timeline seen with antidepressants. Patients who stop taking it after two weeks because they do not notice an immediate effect may be discontinuing before the medication has had time to work.
Atomoxetine is often prescribed when stimulants are contraindicated, when a patient has a history of substance misuse, or when anxiety is a co-occurring condition, and stimulants are aggravating it. It is not a controlled substance.
Viloxazine (Qelbree)
Viloxazine is a newer non-stimulant option FDA-approved for ADHD. It is a selective norepinephrine reuptake inhibitor with some additional serotonin activity. Originally developed as an antidepressant, it was reformulated and approved for ADHD in 2021. It is not a controlled substance and does not carry the same scheduling restrictions as stimulants. Clinical evidence supports its use in both adolescents and adults, and it may be a reasonable option when other non-stimulant choices have not been effective.
Alpha-2 Agonists: Guanfacine and Clonidine
Guanfacine (Intuniv, Tenex) and clonidine (Kapvay, Catapres) are blood pressure medications that also have evidence for reducing ADHD symptoms, particularly impulsivity and hyperactivity. They work on the prefrontal cortex, the area of the brain most involved in executive function. These medications are more commonly used in younger patients or as add-on treatments alongside a primary stimulant or non-stimulant, but they are used in adults as well. They tend to produce sedation, particularly at the start of treatment, which can be useful for patients who also struggle with sleep disruption.
Bupropion (Wellbutrin)
Bupropion is an antidepressant that is sometimes used off-label for ADHD. It affects both dopamine and norepinephrine and can improve focus and attention in some patients, particularly when depression or low mood is also present. It is not FDA-approved for ADHD specifically, but its use in this context is well documented in psychiatric practice. It is not a controlled substance. For patients who cannot tolerate stimulants or who have a co-occurring depressive disorder, bupropion may be a reasonable option to discuss with a psychiatrist.
Stimulant vs. Non-Stimulant: A Direct Comparison
| Factor | Stimulants | Non-Stimulants |
|---|---|---|
| Onset of effect | Hours after the first dose | Weeks of consistent use |
| Controlled substance | Yes (Schedule II) | No (most options) |
| Primary mechanism | Dopamine and norepinephrine increase | Norepinephrine reuptake inhibition (primarily) |
| Common first-line examples | Adderall, Vyvanse, Concerta, Ritalin | Strattera, Qelbree, Intuniv |
| Preferred when | Rapid symptom relief needed; no substance use concerns | Stimulant contraindicated; anxiety co-occurring; substance use history |
| Can be combined | Sometimes, with clinical oversight | Sometimes, with clinical oversight |
How a Psychiatrist Decides Which to Prescribe
The medication decision is not made from a protocol alone. A psychiatrist considers the full clinical picture during an evaluation. This includes the specific ADHD presentation (primarily inattentive, primarily hyperactive-impulsive, or combined), severity of symptoms, how symptoms are affecting daily functioning, any co-occurring conditions such as anxiety, depression, or sleep disorders, cardiovascular history, personal history of substance use, and patient preferences around controlled substances.
Some patients come in with a strong preference for non-stimulant options. Others are primarily concerned with getting symptom relief as quickly as possible. Both are valid. The evaluation is a conversation, not a predetermined outcome. Medication at the first visit is not automatic, and no treatment decision is made without the patient’s understanding and agreement.
If a first medication does not work as expected, that is not the end of the road. Dose adjustments, formulation changes, and switches between medication classes are all standard parts of ongoing ADHD management. A psychiatrist continues to monitor and adjust over time. This iterative process is not a sign of treatment failure. It is how ADHD treatment typically works for a significant portion of patients.
Frequently Asked Questions
What is the difference between stimulant and non-stimulant ADHD medication?
Stimulant medications such as Adderall, Vyvanse, and Concerta increase the availability of dopamine and norepinephrine in the brain and typically produce noticeable effects within hours of the first dose. Non-stimulant options such as Strattera and Qelbree work primarily through norepinephrine and require several weeks of consistent use before full effects are apparent. Stimulants are Schedule II controlled substances, while most non-stimulants are not. The right choice depends on the individual’s symptom profile, medical history, and co-occurring conditions.
Can adults be prescribed stimulants for ADHD through telehealth?
Yes. Board-certified psychiatrists can evaluate and prescribe stimulant medications for ADHD through telehealth appointments. Regulations around controlled substance prescribing via telehealth have evolved since the COVID-19 public health emergency, and the current rules governing this continue to be reviewed at the federal level. At PsychBright Health, telehealth appointments are available to California residents statewide, and prescribing decisions are made by board-certified psychiatrists following a full evaluation. Patients should confirm current prescribing policies when scheduling their appointment.
How long does it take for ADHD medication to work?
Stimulant medications begin working within one to two hours of the first dose in most patients, though finding the right dose and formulation often takes several weeks of adjustment. Non-stimulant medications such as atomoxetine (Strattera) typically require four to eight weeks of consistent daily use before the full therapeutic benefit is felt. Patients who stop a non-stimulant early because they do not notice an immediate response may be discontinuing before the medication has had adequate time to work. A psychiatrist monitors progress and adjusts the plan based on reported results.
What if the first ADHD medication does not work for me?
This is a common experience and does not mean medication cannot help you. ADHD treatment often involves trying more than one medication or adjusting the dose and formulation before finding the right fit. If a stimulant produces intolerable side effects, a different stimulant class or a non-stimulant option is typically the next step. If the initial non-stimulant does not produce adequate improvement after a sufficient trial period, alternatives exist. A psychiatrist reviews what is and is not working at follow-up appointments and adjusts accordingly. The process is collaborative and ongoing.
Are non-stimulant ADHD medications a good option if I have anxiety?
Non-stimulant medications are often the preferred starting point when a patient has both ADHD and an anxiety disorder. Stimulants can exacerbate anxiety symptoms in some individuals, particularly at higher doses or in patients whose anxiety is not well controlled. Atomoxetine and viloxazine do not carry the same risk and may be better tolerated by patients with co-occurring anxiety. That said, some patients with both conditions do well on stimulants with appropriate dose management. The decision depends on the severity of both conditions and is made in consultation with a psychiatrist during the evaluation.
Is it safe to take ADHD medication if I have a history of substance use?
A history of substance use does not automatically disqualify someone from stimulant treatment, but it is an important factor in the prescribing decision. A psychiatrist evaluates the type and recency of substance use, current recovery status, and any co-occurring conditions before making a recommendation. For patients where stimulant prescribing carries additional risk, non-stimulant options such as Strattera or Qelbree may be the more appropriate starting point. Patients in recovery who are also managing ADHD deserve thoughtful, individualized care rather than a blanket refusal to treat.
Does PsychBright Health accept insurance for ADHD treatment?
PsychBright Health accepts Aetna, Blue Shield of California, UnitedHealthcare, Cigna, Anthem, Medicare, and Medicare Advantage. Coverage for psychiatric evaluation and medication management varies by plan and individual policy. To confirm that your specific plan is accepted before scheduling, contact PsychBright Health through the online contact form or by calling the office directly. A staff member can verify your benefits before your first appointment.
Do I need to come in person for an ADHD evaluation and treatment?
No. PsychBright Health offers telehealth appointments to any California resident, so patients across the state can receive a full ADHD evaluation and ongoing medication management without coming to the Los Angeles office in person. In-person appointments are available at the Beverly Drive office for patients who prefer them. Telehealth and in-person options are both provided by board-certified psychiatrists and psychiatric nurse practitioners, not by algorithm-based platforms or unmonitored provider-matching services.
PsychBright Health offers ADHD evaluation and medication management through both telehealth and in-person appointments. If you have questions about whether stimulant or non-stimulant treatment is appropriate for your situation, a board-certified psychiatrist can review your history and discuss the options with you directly. To get started, request an appointment online or call (213) 584-2331.